Author Archives for Sylvain Peysieux

Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases

May 12, 2021 10:00 pm Published by Comments Off on Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases

Daix (France), May 12, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of...


Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

April 26, 2021 10:00 pm Published by Comments Off on Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

Daix (France), April 26, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Inventiva will participate to the upcoming 7th Annual Truist Securities Life Sciences Summit, being held...


Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors

April 19, 2021 10:00 pm Published by Comments Off on Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors

Daix (France), April 19, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA) is pleased to announce the appointment of Martine Zimmermann to its Board of Directors as an independent director. Inventiva’s Board of Directors appointed Martine Zimmerman to replace Nawal Ouzren, who resigned from the Board of Directors in order to focus on the growth of Sensorion. Martine Zimmerman’s appointment...


Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting

March 25, 2021 6:00 pm Published by Comments Off on Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting

Daix (France), March 25, 2021 – Given the current health context, in accordance with the provisions of Order no. 2020-321 of March 25, 2020 adapting the form of meeting and decision-making rules for shareholders meetings and governing bodies of legal entities during the COVID-19 pandemic, as prorogated by Decree no. 2021- 255 of March 9, 2021, Inventiva informs its shareholders...


Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

March 15, 2021 10:00 pm Published by Comments Off on Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

Daix (France), March 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that it had filed its 2020 Universal Registration Document for the year ended December 31, 2020,...


2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

March 4, 2021 10:00 pm Published by Comments Off on 2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

Daix (France), March 4, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its full-year results for 2020. Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2020 has...


Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

February 25, 2021 10:00 pm Published by Comments Off on Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

Daix (France), February 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced a collaboration in the field of NASH biomarkers with Professor Jérôme Boursier, M.D., Ph.D, Professor of...


Inventiva to participate at several investor conferences in March 2021

February 24, 2021 10:00 pm Published by Comments Off on Inventiva to participate at several investor conferences in March 2021

Daix (France), February 24, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will participate at three upcoming investor conferences...


Inventiva’s 2020 Full-Year Financial Results Presentation

February 23, 2021 10:00 pm Published by Comments Off on Inventiva’s 2020 Full-Year Financial Results Presentation

Daix (France), February 23, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company’s full-year financial results for...


Full-Year 2020: Cash position and revenues

February 11, 2021 10:00 pm Published by Comments Off on Full-Year 2020: Cash position and revenues

Daix (France), February 11, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of December 31, 2020 and its 2020 full-year revenues.


Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference

January 6, 2021 10:00 pm Published by Comments Off on Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference

Daix (France), January 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate...


Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

January 5, 2021 10:00 pm Published by Comments Off on Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Daix (France), January 5, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH...


Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

December 7, 2020 10:00 pm Published by Comments Off on Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

Daix (France), December 7, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the beneficial effects of lanifibranor on experimental advanced chronic...


Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 24, 2020 10:00 pm Published by Comments Off on Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Daix (France), November 24, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. During the conference, Inventiva will...


Q3 2020 Financial Information

November 12, 2020 10:00 pm Published by Comments Off on Q3 2020 Financial Information

Daix (France), November 12, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of September 30, 2020 and its revenues for the first nine months...


Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH

November 10, 2020 10:00 pm Published by Comments Off on Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH

Daix (France), November 10, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced conclusions from its end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) for its...


Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference

November 9, 2020 10:00 pm Published by Comments Off on Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference

Daix (France), November 9, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced its participation at the Stifel Virtual Healthcare Conference 2020, being held virtually on November 17-18, 2020,...


Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer

November 5, 2020 10:00 pm Published by Comments Off on Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer

Daix (France), November 5, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer (CMO). He joins Inventiva’s Executive...


Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology

November 2, 2020 10:00 pm Published by Comments Off on Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology

Daix (France), November 2, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the role of peroxisome proliferator-activated receptors (PPARs) in the...


Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020

November 2, 2020 8:00 am Published by Comments Off on Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020

Daix (France), November 2, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that two late-breaking abstracts have been selected for poster presentations during the upcoming The Liver Meeting...